| Citation: |
GAO Yuxia, HE Qian, LI Zhanghuan, LIU Yu, WANG Wenxiang. Effect of human epidermal growth factor receptor 2 on the apoptosis and invasion of ovarian cancer cell and its mechanism[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 11-17. DOI: 10.7619/jcmp.20231682
|
To investigate the effect of human epidermal growth factor receptor 2 (HER2) on apoptosis and invasion of ovarian cancer A2780 and SKOV3 cells and its mechanism.
A total of 27 pairs of ovarian tissues and paracancerous tissues were collected from 27 ovarian cancer patients. Ovarian cancer cells (A2780 cells and SKOV3 cells) and ovarian epithelial cells HOSEpiC were selected as experimental cells. Real-time quantitative polymerase chain reaction (qRT-PCR), Western blot and immunohistochemical techniques were used to detect the expression levels of HER2, E74-like ETS transcription factor 3 (ELF3), sonic hedgehog (SHH) and GLIS family zinc finger protein 1 (GLI1); cell viability, apoptotic rate and invasive ability of A2780 and SKOV3 cells were analyzed by cell counting kit-8 (CCK-8), flow cytometry and Transwell assay, respectively.
HER2 protein and HER2 mRNA expression were higher in ovarian cancer tissues than in paracancerous tissues, the expression of HER2 protein in A2780 cells and SKOV3 cells was higher than that in HOSEPiC cells(P < 0.05). In A2780 and SKOV3 cells, compared with cells transfected with si-NC, the expression level of HER2 protein was decreased in cells transfected with si-HER2, and the cell viability was decreased, the cell apoptosis rate was increased, and the number of invasive cells was decreased (P < 0.05). In A2780 and SKOV3 cells, the expression of ELF3 mRNA in cells transfected with si-HER2 was lower than that in cells transfected with si-NC, and the expression of ELF3 mRNA in cells transfected with si-HER2+ELF3 was higher than that in cells transfected with si-HER2+pcDNA (P < 0.05). Compared with cells transfected with si-NC, the viability of cells transfected with si-HER2 decreased, the apoptosis rate increased, and the number of invasive cells decreased (P < 0.05). Compared with cells transfected with si-HER2+pcDNA, cells transfected with si-HER2+ELF3 had increased viability, decreased apoptosis rate and increased number of invasion cell (P < 0.05). In A2780 and SKOV3 cells, the expression of SHH and GLI1 protein in cells transfected with si-HER2 was lower than that in cells transfected with si-NC, and the expression of SHH and GLI1 protein in cells transfected with si-HER2+ELF3 was higher than that in cells transfected with si-HER2+pcDNA (P < 0.05).
HER2 silencing can promote ovarian cancer cell apoptosis and inhibit cell invasion by regulating the ELF3/SHH pathway, which suggests that inhibition of HER2 expression might be an effective strategy for the treatment of ovarian cancer.
| [1] |
PENNY S M. Ovarian cancer: an overview[J]. Radiol Technol, 2020, 91(6): 561-575.
|
| [2] |
KOSSAï M, LEARY A, SCOAZEC J Y, et al. Ovarian cancer: a heterogeneous disease[J]. Pathobiology, 2018, 85(1/2): 41-49.
|
| [3] |
TIMMERMANS M, SONKE G S, VAN DE VIJVER K K, et al. No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands[J]. Eur J Cancer, 2018, 88: 31-37. doi: 10.1016/j.ejca.2017.10.030
|
| [4] |
YARDEN Y, SLIWKOWSKI M X. Untangling the ErbB signalling network[J]. Nat Rev Mol Cell Biol, 2001, 2(2): 127-137. doi: 10.1038/35052073
|
| [5] |
LOIBL S, GIANNI L. HER2-positive breast cancer[J]. Lancet, 2017, 389(10087): 2415-2429. doi: 10.1016/S0140-6736(16)32417-5
|
| [6] |
VRANIC S, BEŠLIJA S, GATALICA Z. Targeting HER2 expression in cancer: new drugs and new indications[J]. Bosn J Basic Med Sci, 2021, 21(1): 1-4.
|
| [7] |
MOMENY M, ZARRINRAD G, MOGHADDASKHO F, et al. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells[J]. Sci Rep, 2017, 7(1): 4204. doi: 10.1038/s41598-017-04147-0
|
| [8] |
WANG K, GUAN C N, YU J H, et al. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(43): 75528-75543. doi: 10.18632/oncotarget.20657
|
| [9] |
SEO S H, HWANG S Y, HWANG S, et al. Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R[J]. EMBO Rep, 2022, 23(8): e52977. doi: 10.15252/embr.202152977
|
| [10] |
YEUNG T L, LEUNG C S, WONG K K, et al. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells[J]. Oncotarget, 2017, 8(10): 16951-16963. doi: 10.18632/oncotarget.15208
|
| [11] |
KOTULAK-CHRZASZCZ A, KMIEC Z, WIERZBICKI P. Sonic Hedgehog signaling pathway in gynecological and genitourinary cancer (Review)[J]. Int J Mol Med, 2021, 47(6): 106. doi: 10.3892/ijmm.2021.4939
|
| [12] |
ZENG C Y, CHEN T T, ZHANG Y, et al. Hedgehog signaling pathway regulates ovarian cancer invasion and migration via adhesion molecule CD24[J]. J Cancer, 2017, 8(5): 786-792. doi: 10.7150/jca.17712
|
| [13] |
PERRIER A, GLIGOROV J, LEFÈVRE G, et al. The extracellular domain of Her2 in serum as a biomarker of breast cancer[J]. Lab Invest, 2018, 98(6): 696-707. doi: 10.1038/s41374-018-0033-8
|
| [14] |
HOLTEN-ROSSING H, MØLLER TALMAN M L, KRISTENSSON M, et al. Optimizing HER2 assessment in breast cancer: application of automated image analysis[J]. Breast Cancer Res Treat, 2015, 152(2): 367-375. doi: 10.1007/s10549-015-3475-3
|
| [15] |
蔺楠, 任超, 蔡炯. HER2在上皮性卵巢癌中的研究进展[J]. 标记免疫分析与临床, 2019, 26(8): 1418-1423. https://www.cnki.com.cn/Article/CJFDTOTAL-BJMY201908039.htm
|
| [16] |
周许阳, 张媛. HER2靶向治疗在卵巢癌中的研究进展[J]. 中国现代医生, 2023, 61(3): 111-115. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202303027.htm
|
| [17] |
MENON S S, GURUVAYOORAPPAN C, SAKTHIVEL K M, et al. Ki-67 protein as a tumour proliferation marker[J]. Clin Chim Acta, 2019, 491: 39-45. doi: 10.1016/j.cca.2019.01.011
|
| [18] |
WANG H, YU Z Q, HUO S F, et al. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer[J]. Int J Biochem Cell Biol, 2018, 94: 98-106. doi: 10.1016/j.biocel.2017.12.002
|
| [19] |
ZHANG Y N, WANG X, CHEN X C. Identification of core genes for early diagnosis and the EMT modulation of ovarian serous cancer by bioinformatics perspective[J]. Aging, 2021, 13(2): 3112-3145. doi: 10.18632/aging.202524
|
| [20] |
LIU Y, WANG S R, ZHOU R Q, et al. Overexpression of E74-like transformation-specific transcription factor 3 promotes cellular proliferation and predicts poor prognosis in ovarian cancer[J]. Oncol Lett, 2021, 22(4): 710. doi: 10.3892/ol.2021.12971
|
| [21] |
KUANG L, LI L A. E74-like factor 3 suppresses microRNA-485-5p transcription to trigger growth and metastasis of ovarian cancer cells with the involvement of CLDN4/Wnt/β-catenin axis[J]. Saudi J Biol Sci, 2021, 28(8): 4137-4146. doi: 10.1016/j.sjbs.2021.04.093
|
| [22] |
KAR A, GUTIERREZ-HARTMANN A. ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells[J]. Oncotarget, 2017, 8(41): 69622-69640. doi: 10.18632/oncotarget.18710
|
| [23] |
PAN Y B, ZHOU J N, ZHANG W D, et al. The Sonic Hedgehog signaling pathway regulates autophagy and migration in ovarian cancer[J]. Cancer Med, 2021, 10(13): 4510-4521. doi: 10.1002/cam4.4018
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: